HASBROUCK HEIGHTS, N.J., March 11, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2009. Nymox reported a net loss of $5,130,074, or $0.17 per share for the year ended December 31, 2009, compared to $4,637,103, or $0.16 per share for same period in 2008. The increase of the net loss for the year is attributable to expenses relating to the launch of Phase 3 clinical trials for NX-1207. Net losses include stock compensation charges of $1,085,164 in 2009 and $925,220 in 2008. Product sales amounted to $415,980 for the year ended December 31, 2009, compared to $426,675 for the same period in 2008. The weighted average number of common shares at the year ended December 31, 2009 was 30,717,822, compared to 29,749,000 at December 31, 2008.
